MedPath
HSA Approval

CANESPRO ONCE DAILY CREAM 1%

SIN15415P

CANESPRO ONCE DAILY CREAM 1%

CANESPRO ONCE DAILY CREAM 1%

February 1, 2018

BAYER (SOUTH EAST ASIA) PTE LTD

BAYER (SOUTH EAST ASIA) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantBAYER (SOUTH EAST ASIA) PTE LTD
Licence HolderBAYER (SOUTH EAST ASIA) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
General Sale List
HSA Singapore Classification

Formulation Information

CREAM

**Dosage & application** Posology To achieve a lasting cure, treatment with bifonazole must be carried out reliably and over an adequate period. The usual periods of treatment are summarized in the table below: ![Canespro Dosage Table 1](https://cdn.medpath.com/drug/dosage/20240520/5e4ce1918718ba9fe26998dbcc3bfe16.png) **Method of administration** Once a day, preferably in the evening, before going to bed. It should be applied thinly to the affected skin area and rubbed in. A small amount of cream is generally sufficient to treat an area of about the size of the palm of hand. **Use in Children** No in-depth studies have been performed in the pediatric population (0 to 18 years). From a survey of the clinical data reported there is no indication that harmful effects should be anticipated in pediatric population. However, in neonates (0 to 27 days), infants and toddlers (28 days to 23 months), the medicinal product should only be used under medical supervision.

TOPICAL

Medical Information

**Indications** - Treatment of skin mycoses caused by dermatophytes, yeasts, moulds, and other fungi (e.g. athlete's foot, fungal infection of the hand, ringworms, jock itch, white spots, superficial fungal skin infections & other tinea conditions). - Treatment of erythrasma (skin redness).

**Contraindication** Hypersensitivity to the active substance or to any of the excipients.

D01AC10

bifonazole

Manufacturer Information

BAYER (SOUTH EAST ASIA) PTE LTD

GP Grenzach Produktions GmbH

Kern Pharma, S.L.

Active Ingredients

Bifonazole micronized

1.00%

Bifonazole

Documents

Patient Information Leaflets

Canespro Once Daily Cream 1% - PIL.pdf

Approved: July 29, 2022

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.